ライフサイエンスコーパス: betamethasone

1 ve lumbar nerve blocks with triamcinolone or betamethasone.

2 ng volumes for two, three, and four doses of betamethasone.

3 volume after fetal exposure to four doses of betamethasone.

4 d dexamethasone 4-9 mg/day for 3-19 weeks or betamethasone 12-24 mg/week for >6 weeks (group A).

5 rse were randomly assigned to receive either betamethasone, 12 mg intramuscularly repeated once in 24

6 course of antenatal corticosteroids (either betamethasone, 12 mg intramuscularly repeated once in 24

7 First, the in vitro release of betamethasone-17-valerate (BMV), a representative dermat

8 e patients received a mixture of 1 mL of the betamethasone, 6 mg/mL, and 1 mL of 0.5% bupivacaine hyd

9 It is not known whether betamethasone administered to women at risk for late pre

10 drift-times for the protonated diastereomers betamethasone and dexamethasone are reproducibly differe

11 Both betamethasone and dexamethasone induce similar increases

12 cific differences, if any, in the actions of betamethasone and dexamethasone of measured fetal respon

13 Our results indicate that prenatal betamethasone and dexamethasone treatment of late-gestat

14 The fall in fetal breathing during betamethasone and dexamethasone treatment was not associ

15 fetal blood pressure occurred following both betamethasone and dexamethasone treatment.

16 nd adrenaline concentrations occurred during betamethasone and dexamethasone treatment.

17 ts of fetal treatment with clinical doses of betamethasone and dexamethasone; (2) define specific dif

18 ric changes in the lungs of lambs exposed to betamethasone and T4 48 h before preterm delivery at 121

19 Selective nerve root blocks with betamethasone and triamcinolone reduced low back pain an

20 Corticosteroids (such as betamethasone) and magnesium sulphate (MgSO4) are admini

21 d 76% at 2 weeks with vehicle, pimecrolimus, betamethasone, and clobetasol, respectively, with parall

22 domized to receive saline (controls) or 6 mg betamethasone (beta) 48 and 24 h before delivery at 125

23 flexion spasms based on prenatal exposure to betamethasone combined with postnatal administration of

24 Prenatal treatment with MgSO4/betamethasone confers long-term benefits beyond cerebral

25 were randomly assigned to weekly courses of betamethasone, consisting of 12 mg given intramuscularly

26 xpectedly high percentage of those receiving betamethasone-containing dermatologic preparations had d

27 ibavirin and interferon alfa-2b, and various betamethasone-containing dermatologic preparations.

28 a similar extent as a positive control 0.1% betamethasone dipropionate ointment.

29 igator site daily for 14 days: pimecrolimus, betamethasone dipropionate, clobetasol propionate, and a

30 Prenatal betamethasone exposure sensitizes rats to development of

31 s farinae were divided into six groups: 1) a betamethasone group (betamethasone ointment, six times a

32 curred in 165 of 1427 infants (11.6%) in the betamethasone group and 202 of 1400 (14.4%) in the place

33 Neonatal hypoglycemia was more common in the betamethasone group than in the placebo group (24.0% vs.

34 ) in the placebo group (relative risk in the betamethasone group, 0.80; 95% confidence interval [CI],

35 ccurred significantly less frequently in the betamethasone group.

36 as follows: triamcinolone > dexamethasone > betamethasone > hydrocortisone.

37 The pronounced betamethasone-induced fetal hypertension is associated w

38 Following baseline, either saline (n = 9), betamethasone (n = 9), or dexamethasone (n = 6) was infu

39 significantly improved as compared with the betamethasone ointment and placebo groups.

40 ally, three times a week), 3) an FTY720 plus betamethasone ointment group, 4) an ointment base group

41 In the FTY720 plus betamethasone ointment group, the dermatitis was signifi

42 suggest that the combination of FTY720 plus betamethasone ointment is a promising candidate for trea

43 d into six groups: 1) a betamethasone group (betamethasone ointment, six times a week), 2) an FTY720

44 Pregnant rats received two doses of betamethasone on day 15 of gestation.

45 occurred during fetal treatment with either betamethasone or dexamethasone.

46 s were assigned to receive two injections of betamethasone or matching placebo 24 hours apart.

47 domized to receive 1 to 4 doses of 0.5 mg/kg betamethasone or saline placebo at 7 d intervals from 10

48 , 42% of triamcinolone recipients and 58% of betamethasone recipients demonstrated improvement in low

49 , 42% of triamcinolone recipients and 53% of betamethasone recipients had improvement in low back pai

50 , 45% of triamcinolone recipients and 58% of betamethasone recipients had improvement in low back pai

51 s 49% of triamcinolone recipients and 55% of betamethasone recipients had improvement in lower extrem

52 s 52% of triamcinolone recipients and 57% of betamethasone recipients had improvement in lower extrem

53 s 55% of triamcinolone recipients and 57% of betamethasone recipients had lower extremity pain improv

54 Administration of betamethasone to women at risk for late preterm delivery

55 Lung function for six control and six betamethasone-treated animals was similar.

56 Betamethasone treatment had little effect, confirming th

57 ive femoral vasoconstriction occurred during betamethasone treatment.

58 tion and the effectiveness of prenatal MgSO4/betamethasone treatments between males and females in a

59 Three steroids (betamethasone, triamcinolone, and methylprednisolone) an

60 We recently showed that betamethasone valerate (BM) although clinically more eff

61 Unlike betamethasone valerate (BMV), long-term NF-kappaB Decoy

62 (Fingolimod), alone and in combination with betamethasone valerate ointment, in the NC/Nga mouse mod

63 Betamethasone valerate resulted in a significant reducti

64 ne, boldenone, trenbolone, testosterone, and betamethasone were chosen as study compounds.